Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ORIG3N logo — company profile

ORIG3N

Founded 2014 Venture round Total: $76.17M Biotechnology, Health Care +1

General Information

Company Name ORIG3N
Founded Year 2014
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with ORIG3N. To contact ORIG3N, visit orig3n.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About ORIG3N

ORIG3N is a biotechnology company founded in 2014 and based in Boston, Massachusetts. The company focuses on developing breakthrough treatments for rare genetically inherited diseases, with targets in heart, liver, and neurodegenerative indications. Their latest milestone was a significant $26.17M Venture Round investment on September 9, 2020, with Sekhmet Ventures as the investor. ORIG3N's dedication to addressing unmet medical needs in the field of rare diseases positions it as an intriguing prospect for venture capitalists seeking to support innovative approaches in healthcare and biotechnology.

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $26.17M 1
Sekhmet Ventures
Sekhmet Ventures
09 Sep 2020
Series B $14.40M 9
Hatteras Venture Partners KTB Ventures 180 Degrees Capital
Hatteras Venture Partners, KTB Ventures +7
12 Jul 2018
Venture Round $20.00M -
27 Jun 2017
Series A $12.50M -
12 Dec 2015
Venture Round $3.10M -
05 Feb 2015

ORIG3N Alternatives & Competitors

View All Alternatives
ORIG3N vs
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals

Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.

Post-IPO Equity
201-500 employees
Biotechnology, Health Care
ORIG3N vs
Vigil Neuroscience
Vigil Neuroscience United States

Harnessing the power of microglia to transform treatments for neurodegenerative diseases

Acquired
76 employees
Biotechnology, Health Care
ORIG3N vs
Merck & Co., Inc.
Merck & Co., Inc.

Merck develops and produces medicines, vaccines, biologic therapies and animal health products

IPO
92 employees
Biotechnology, Health Care
View all alternatives

FAQ About ORIG3N

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.
ORIG3N was founded in 2014.
ORIG3N operates in Biotechnology, Health Care and Health and Wellness.
ORIG3N has completed 5 funding rounds, raising a total of $76.17M. The latest funding stage is Venture round.
Top alternatives and competitors to ORIG3N include Dicerna Pharmaceuticals, Vigil Neuroscience, Merck & Co., Inc., Nobias Therapeutics, SIWA Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ORIG3N and Dicerna Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ORIG3N, https://bouncewatch.com/company/orig3n, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes